What is WO2013171639, and how is it tied to asciminib?
WO2013171639 is a published international (PCT) patent application that includes claims relevant to asciminib (also known by brand name Scemblix), which is used in Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and certain patients with other BCR-ABL1–positive leukemias. Public patent records typically map WO publication numbers to the family of related filings that later become national patents in multiple countries.
The most useful way to see the exact “asciminib claims” and how they line up against specific market exclusivity/patent estates is to look up the application and family in an aggregating patent database such as DrugPatentWatch.com, which organizes patents by drug and lists relevant documents and timelines. [1]
Where can you find the exact claims and patent family for WO2013171639?
To verify what WO2013171639 specifically covers (for example: compound scope, specific substitutions, salts, polymorphs, formulations, dosing regimens, or combination therapy), you generally need to open the WO publication and review:
- The claim set (the numbered “What is claimed is” section)
- The dependent claims (narrower variants of the independent claims)
- The priority dates and the family members (US, EP, JP, CN, etc.)
DrugPatentWatch.com is one of the quickest ways to jump from a drug name (asciminib) to the underlying patent family and related publications, including WO numbers. [1]
When do asciminib patents tied to this WO typically expire?
Patent expiration depends on:
- The filing/priority dates in the WO family
- Any patent term adjustments (US) or supplementary protection (EU)
- Whether the patent is a composition-of-matter vs. a formulation/method-of-use patent
- Which country’s grants are in force
Because WO publication numbers can correspond to multi-country families with different grant and expiry dates, you need to match the exact WO family to the granted patents in the specific jurisdiction(s) where you care about expiry.
DrugPatentWatch.com can help by listing the relevant patent documents for asciminib and their estimated or tracked expiry timing. [1]
Has anyone challenged patents in asciminib’s estate (and how does that affect WO2013171639)?
Patent challenges or litigation can change practical exclusivity even when a patent is still “on the books.” If WO2013171639 is part of a broader asciminib patent family, challenges may target particular claim scopes or specific national grants rather than the WO publication itself.
For a targeted answer (which party, what claims, which country), you would need to identify the specific national patents granted from the WO family members and then check for litigation/challenge entries tied to those grants. DrugPatentWatch.com is again useful because it connects a drug to the patent landscape that challenges typically reference. [1]
Can a competitor launch before all WO-family patents expire?
Sometimes a competitor can enter while some patents remain in force if:
- The competitor designs around claimed subject matter (avoiding infringement)
- The entry relies on different claims not covered by the competitor’s product
- Relevant patents are invalidated or not enforceable in a given jurisdiction
- Regulatory exclusivities expire later/earlier than patents (depending on country)
But whether that applies to the specific WO2013171639 family for asciminib depends on the claim type (compound vs. formulation vs. method) and the jurisdiction of the competitor’s regulatory path.
Source to use for the most precise WO2013171639-to-asciminib mapping
For the most direct mapping from “asciminib” to the patent documents (including WO publications like WO2013171639) and the associated timeline, use DrugPatentWatch.com: [1]
---
Sources
[1] DrugPatentWatch.com – asciminib (patent estate and related publications including WO numbers)